Akebia Therapeutics announced that it has regained full rights to the oral drug Vafseo (vadadustat) for chronic kidney disease anemia after its commercialization partner CSL Vifor agreed to terminate their contract.
Tag Archive for: Akebia
The FDA’s busy March continues with six target action dates remaining on the calendar. Over the next two weeks, the regulator will decide on investigational therapies for Duchenne muscular dystrophy, chronic kidney disease anemia, a rare metabolic disorder and more.